340B Webinar Delivers Critical Insights on Federal Program - Watch the Recordings
Oregon’s SB 533 and HB 2385 claim to protect the 340B Drug Pricing Program, but the reality is far more complex. These bills could disrupt access to discounted medications, create conflicts with federal law, and ultimately harm the very patients the 340B program is meant to serve.
The 340B program is a federal program that has experienced significant growth in the past several years, meaning potential savings are being redirected from benefiting patients to other entities including pharmacy middlemen or large health systems instead of ensuring only patients receive the benefits.
Unfortunately, these bills will only make it more difficult to ensure oversight and creates more potential for abuse or inequitable results
Watch key highlights of Oregon Bio's recent webinar to hear from industry experts on why these bills may do more harm than good.
To take a deeper dive, watch the complete webinar, posted below. Our panelists present a brief 340B program history, break down the unintended consequences of these bills and discuss ongoing federal litigation.
Full recording April 25 webinar:
Program
Oregon Legislative Update on 340B Bills (as of 04/25/2025)
- Rocky Dallum, Partner - Government Relations & Public Policy Practice Group, Tonkon Torp
The Federal 340B Program - Overview
- Brenda Gleason, President and Founder, M2 Health Care Consulting
Moderated Discussion
- Brenda Gleason - Moderator
- Shawn Gremminger, President and CEO, National Alliance of Healthcare Purchaser Coalitions
- Jen Laws, President & CEO, Community Access National Network
- Kalvin Pugh, State Policy Consultant, Community Access National Network
Topic Covered During this Webinar:
- 340B overview: how lack of oversight and transparency has undermined the program
- Federal reform update: 340B is a federal program that requires a federal fix
- Call to action: why proposed Oregon legislation will worsen existing problems with the program and delay needed federal reform